Novartis’ Bold Move: Acquiring Potential Game-Changer in Breast Cancer Treatment
In a significant move within the pharmaceutical sector, Novartis has struck a deal to acquire SNV4818, a…
Roche oral SERD giredestrant boosts iDFS in early breast cancer
Roche (OTCQX: RHHBY) reported positive Phase III results from the lidERA trial of…
Roche presents details on breast cancer pill giredestrant
Roche has unveiled detailed data for its oral selective estrogen receptor degrader (SERD), giredestrant, at the 2025 San…